Stocktwits37d agobullish
CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B AcquisitionThe deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing price on Monday.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
309last 24h
2121last 7d
378● bullish (7d)
182● bearish (7d)
204publishers
Investing.com37d agobullish
Crinetics soars on $10B acquisition by VertexInvesting.com -- Vertex Pharmaceuticals Incorporated announced Monday it will acquire Crinetics Pharmaceuticals, Inc. for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired.